AVBP
ArriVent BioPharma Inc.

137
Mkt Cap
$1.07B
Volume
298,406.00
52W High
$27.22
52W Low
$15.47
PE Ratio
-5.45
AVBP Fundamentals
Price
$24.01
Prev Close
$24.31
Open
$24.26
50D MA
$22.64
Beta
0.94
Avg. Volume
473,781.21
EPS (Annual)
-$4.32
P/B
3.36
Rev/Employee
$0.00
$461.06
Loading...
Loading...
News
all
press releases
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP
Hidden Lake Asset Management LP cut its stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 48.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research
BTIG Research reissued a "buy" rating and set a $42.00 target price on shares of ArriVent BioPharma in a research report on Thursday...
MarketBeat·6d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume - Here's What Happened
ArriVent BioPharma (NASDAQ:AVBP) Sees Strong Trading Volume - Here's Why...
MarketBeat·8d ago
News Placeholder
Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 70.4% in ArriVent BioPharma, Inc. (AVBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·8d ago
News Placeholder
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their sector so far this year.
Zacks·8d ago
News Placeholder
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer
Oppenheimer reiterated an "outperform" rating and set a $50.00 price objective (up from $44.00) on shares of ArriVent BioPharma in a research note on Friday...
MarketBeat·12d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00
Citigroup raised their price objective on ArriVent BioPharma from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday...
MarketBeat·12d ago
News Placeholder
ArriVent BioPharma Sees Unusually High Options Volume (NASDAQ:AVBP)
ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) saw unusually large options trading activity on Friday. Stock investors acquired 1,832 call options on the stock. This is an increase of...
MarketBeat·12d ago
News Placeholder
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00
HC Wainwright boosted their target price on shares of ArriVent BioPharma from $42.00 to $44.00 and gave the stock a "buy" rating in a report on Friday...
MarketBeat·12d ago
News Placeholder
ArriVent Biopharma, Inc. Full Year Loss Increases
(RTTNews) - ArriVent Biopharma, Inc. (AVBP) reported Loss for its full year of -$166.31 million...
Nasdaq News: Markets·12d ago
<
1
2
...
>

Latest AVBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.